US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
ドイツ
TG
Inventiva (6IV) 銘柄情報

Inventiva (6IV)

3.42

0.045

(1.33%)

終了 6月15日 5:00AM

Inventiva (6IV) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

3.42

( 1.33% )

買値

3.39

売値

3.45

出来高

4,228

3.30 日の範囲 3.515

2.595 52 週間の範囲 6.16

時価総額

前日終値

3.375

始値

3.40

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

350,036 €

発行済株式数

207,707,475

配当利回り

PER

-1.8

1 株当たり利益 (EPS)

-1.9

歳入

6.76M

純利益

-354.14M

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome prolifer... Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

inventivapharma.com

本社

Daix, France

設立

2026

Inventiva is listed in the Healthcare sector of the Tradegate (DE) with ticker 6IV. The last closing price for Inventiva was 3.38 €. Over the last year, Inventiva shares have traded in a share price range of 2.595 € to 6.16 €.

Inventiva currently has 207,707,475 shares in issue. The market capitalisation of Inventiva is 710.36 € million. Inventiva has a price to earnings ratio (PE ratio) of -1.80.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.255	-6.9387755102	3.675	3.675	3.19	2493	3.42053755	DE
4	-1.42	-29.3388429752	4.84	4.8499999	3.115	1861	3.88857446	DE
12	-1.82	-34.7328244275	5.24	5.26	3.115	1391	4.25614605	DE
26	-0.435	-11.2840466926	3.855	6.16	3.115	2341	4.74523378	DE
52	0.505	17.3241852487	2.915	6.16	2.595	3021	4.16857388	DE
156	0.155	4.74732006126	3.265	6.16	1.452	1932	3.7013614	DE
260	0.155	4.74732006126	3.265	6.16	1.452	1932	3.7013614	DE

6IV - Frequently Asked Questions (FAQ)

What is the current Inventiva share price?

The current share price of Inventiva is 3.42 €

How many Inventiva shares are in issue?

Inventiva has 207,707,475 shares in issue

What is the market cap of Inventiva?

The market capitalisation of Inventiva is EUR 710.36M

What is the 1 year trading range for Inventiva share price?

Inventiva has traded in the range of 2.595 € to 6.16 € during the past year

What is the PE ratio of Inventiva?

The price to earnings ratio of Inventiva is -1.8

What is the cash to sales ratio of Inventiva?

The cash to sales ratio of Inventiva is 105.07

What is the registered address of Inventiva?

The registered address for Inventiva is 50 rue de Dijon, Daix, Burgundy, 21121

What is the Inventiva website address?

The website address for Inventiva is inventivapharma.com

Which industry sector does Inventiva operate in?

Inventiva operates in the Biotechnology & Life Sciences sector

ddls

In reality Biel PPS is in freeze position. Monday morning trades will show that, and you will look like a pump monkey.

HGiLS

My point of view is that Eliquis will not be sold by elite but by the company that will buy elite. No one knows what will be the market value of Eliquis in 1.2 or 5 years from now because we don’t know if Pfizer will play ball like Purdue or play fair.

The pr says 26 billion let the

Snoopcad105

Snoopcad105 3分前

So on LinkedIn 2 people from Parker Institute for Cancer Immunotherapy will be on the Today show talking about "Breast Cancer Vaccine Latest with Kristen Dahlgren and Dr. Karen Knudsen". That is the same group who held the cancer vaccine breakfast on capital hill last week. Time frame shows 7-9AM

Helter Skelter

Helter Skelter 8分前

"NVIDIA acts as a distributor for QNX" 😂

https://investorshub.advfn.com/uimage/uploads/2026/6/14/sxrjfBB_Nvidia_a_DISTRIBUTOR_lol_061426.png

The THOR 🏆️ QNX Market (Monopolization)

https://investorshub.advfn.com/uimage/uploads/2026/6/4/bzv

Pittsburgh Boy

Pittsburgh Boy 10分前

Wow!! 362,000 reads in last 24 hours for a scam stock is truly amazing!!

Investor082

Investor082 12分前

You omitted 10 year survival data, tax savings, higher reimbursement rates, and other nuggets you were pumping last year. Any update on those pieces?

By the way, Dr. Jenkins is kind of small league now. The companies she sits on board over the last many years are all struggling w

BIOChecker4

BIOChecker4 12分前

Goal posts were moved and endpoints were changed multiple times. The reviewers at the EMA were unconvinced. That is how we know.

Large, well designed Phase 3 trials are a must.

Live in denial if it makes you feel better.

joyceschoice

joyceschoice 13分前

https://www.youtube.com/watch?v=DAcHulzp6SA

Elite finance - the base wonder of the world.

mrwrn2010

mrwrn2010 20分前

We would all be well served to be conservative in our estimates and then be surprised to the upside. That’s not bashing, it’s just realism. Vyvanse was pegged as a 5.1B market and though Elite doesn’t break out revenues by product, we clearly are at a small fraction of that in *total* revenues, Vyva

Investor082

Investor082 21分前

Agreed, 90% or so are paid pumpers with multiple IDs. Their job is to defend managements lies and poor performance at all cost. Who cares about losing money and opportunity cost, LOL! ;)

LiveFromThe416

LiveFromThe416 24分前

Will it be another short ~2 years? only the traders, and fake longs (shorts- you?), care about the week-to-week. Longs are looking forward to 2027+.

Vexari

Vexari 26分前

5 natural fertilizers that work Instantly

When perceived dead plants

www.youtube.com/watch?v=RUtAxDdT0zY Come back to life

https://www.youtube.com/watch?v=RUtAxDdT0zY (27:03)

Worth the watch

For gardeners

DrSleep

DrSleep 26分前

Would it not be more reasonable to gauge value from the relative pricing endpoint than the temporary higher generic entry pricing? Emphasis on temporary.

SDCRBS

SDCRBS 27分前

🟩 Why investors care: VeeMost is building what CDW doesn’t have
CDW wins today because of:

15,000 employees

massive sales teams

decades of relationships

brute-force manpower

But CDW does not have:

uplata

uplata 28分前

If Today's war News real?

Market will be sell the news all priced.

Let see 30m charts will tell the story..

velcro

velcro 28分前

All major Index Futures are up HUGE.

waterpro42

waterpro42 29分前

Big volume in Aussieland out the gate and greeeen!

HGiLS

Hi kayak sorry for that one I did not remember your position on jour’s minimization on Eliquis.

SDCRBS

SDCRBS 31分前

🔥 Investor Critical Summary: Why VeeMost Matters Right Now

➡️️ The synergistic platforms create a flywheel CDW does NOT have
Melvin is expanding capabilities across three interconnected platforms:

A. VeeBids (AI bid discovery + automation)
Find

sam1933

sam1933 33分前

This adds a whole new level..$HBAR, NVIDIA, Space X and Saudi Arabia
While the markets are bleeding, $HBAR is powering Saudi Arabia’s &

BlueChip$

BlueChip$ 34分前

More than 75 data center build-outs worth $130 billion have been successfully blocked in the first three months of 2026 — bipartisan opposition mounts nationwide over fears of soaring power and water costs | Tom's Hardware https://share.google/yGZ3087Tov7PtUfy4

D-Mike

D-Mike 37分前

You’re an overpaid basher idiot. Go away.

WhiteOwl

WhiteOwl 38分前

I’m a little disappointed in Michael’s. I questioned the lack of substance in his tweets like others have questioned him and he blocked me from future Replies to comments. I legitimately questioned the constant banter with no substance just like others have done. This does not give me much confid

DAXsector All Pharma and...

Bmo Balanced Etf Portfol...

Pan Global Resources

WisdomTree Japan Equity ...

Evergrande Property Serv... (PK)

Invinity Energy Systems

Borregaard ASA (PK)

Sitio Royalties

HSBC MSCI Emerging Marke...

High Point Exploration

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。